Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Catalent misses Q1 revenue estimates
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates
Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
Catalent reports Q1 loss, misses market expectations
Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations. The company posted a loss per share of $0.13,
1d
on MSN
EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6
By Foo Yun Chee and Maggie Fick BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear ...
BioSpace
12d
Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...
Business Insider
7h
Catalent Inc. Reports Q1 Fiscal 2025 Results
Catalent
Inc ( (CTLT)) has released its Q1 earnings. Here is a breakdown of the information
Catalent
Inc presented to its investors.
Catalent
Inc., a leading global contract development and ...
6d
Backlash builds against Novo’s Catalent takeover
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...
FiercePharma
13d
Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...
18h
Catalent reports Q1 EPS (13c), consensus 5c
Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...
STAT
2d
Pharmalittle: We’re reading about a weight loss pill, the FDA warning a compounder, and more
And please do keep in touch. … European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ ...
6d
Catalent to sell New Jersey drug facility to Ardena
Ardena, a Belgium-based pharmaceutical contract manufacturer, will acquire Catalent’s facility in Somerset, New Jersey, ...
13d
on MSN
Roche CEO says antitrust regulators should block Catalent sale to Novo Holdings (update)
Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...
BioSpace
13d
Roche Beats Q3 Sales Estimates as CEO Voices Opposition to Novo Holdings’ Catalent Buyout
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Novo Nordisk
Wegovy
CTLT
Feedback